| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants.
|
Nat Genet
|
2007
|
12.62
|
|
2
|
Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
|
N Engl J Med
|
2002
|
6.26
|
|
3
|
Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci.
|
Nat Genet
|
2010
|
3.58
|
|
4
|
Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
|
Arthritis Rheum
|
2006
|
3.51
|
|
5
|
Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial.
|
Arthritis Rheum
|
2008
|
2.48
|
|
6
|
Genome sequence of the saprophyte Leptospira biflexa provides insights into the evolution of Leptospira and the pathogenesis of leptospirosis.
|
PLoS One
|
2008
|
2.35
|
|
7
|
Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET).
|
Arthritis Rheum
|
2005
|
2.03
|
|
8
|
ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis.
|
Am J Med
|
2007
|
1.94
|
|
9
|
Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis.
|
Ann Intern Med
|
2007
|
1.73
|
|
10
|
Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial.
|
Arthritis Rheum
|
2006
|
1.64
|
|
11
|
The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event.
|
J Rheumatol
|
2007
|
1.62
|
|
12
|
IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis.
|
Proc Natl Acad Sci U S A
|
2011
|
1.61
|
|
13
|
Are there gender differences in severity of ankylosing spondylitis? Results from the PSOAS cohort.
|
Ann Rheum Dis
|
2006
|
1.47
|
|
14
|
Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial.
|
Arthritis Rheum
|
2002
|
1.39
|
|
15
|
Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study.
|
Ann Intern Med
|
2005
|
1.30
|
|
16
|
Risk factors for functional limitations in patients with long-standing ankylosing spondylitis.
|
Arthritis Rheum
|
2005
|
1.26
|
|
17
|
A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis.
|
Arthritis Care Res (Hoboken)
|
2011
|
1.23
|
|
18
|
MRI of the sacroiliac joints in patients with moderate to severe ankylosing spondylitis.
|
AJR Am J Roentgenol
|
2006
|
1.22
|
|
19
|
Clinical and immunogenetic prognostic factors for radiographic severity in ankylosing spondylitis.
|
Arthritis Rheum
|
2009
|
1.21
|
|
20
|
Herpes zoster in immunocompromised patients: incidence, timing, and risk factors.
|
Am J Med
|
2005
|
1.16
|
|
21
|
International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis.
|
J Rheumatol
|
2007
|
1.11
|
|
22
|
Psychological correlates of self-reported functional limitation in patients with ankylosing spondylitis.
|
Arthritis Res Ther
|
2009
|
1.08
|
|
23
|
Breaking a paradigm: male-produced aggregation pheromone for the Colorado potato beetle.
|
J Exp Biol
|
2002
|
1.05
|
|
24
|
International spondyloarthritis interobserver reliability exercise--the INSPIRE study: I. Assessment of spinal measures.
|
J Rheumatol
|
2007
|
1.04
|
|
25
|
Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's).
|
Arthritis Care Res (Hoboken)
|
2012
|
0.99
|
|
26
|
Development and validation of a case ascertainment tool for ankylosing spondylitis.
|
Arthritis Care Res (Hoboken)
|
2010
|
0.99
|
|
27
|
A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis.
|
Arthritis Rheum
|
2005
|
0.98
|
|
28
|
Impact of ankylosing spondylitis on work and family life: comparisons with the US population.
|
Arthritis Rheum
|
2008
|
0.98
|
|
29
|
Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS).
|
J Rheumatol
|
2008
|
0.97
|
|
30
|
Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton's tyrosine kinase inhibitor.
|
Drug Metab Dispos
|
2011
|
0.96
|
|
31
|
Responsiveness and discriminative capacity of the assessments in ankylosing spondylitis disease-controlling antirheumatic therapy core set and other outcome measures in a trial of etanercept in ankylosing spondylitis.
|
Arthritis Rheum
|
2004
|
0.93
|
|
32
|
Occupational physical activities and long-term functional and radiographic outcomes in patients with ankylosing spondylitis.
|
Arthritis Rheum
|
2008
|
0.93
|
|
33
|
Assessment of the item selection and weighting in the Birmingham vasculitis activity score for Wegener's granulomatosis.
|
Arthritis Rheum
|
2008
|
0.93
|
|
34
|
Psychological correlates of self-reported disease activity in ankylosing spondylitis.
|
J Rheumatol
|
2010
|
0.92
|
|
35
|
Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.
|
J Rheumatol
|
2005
|
0.92
|
|
36
|
Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's).
|
Arthritis Care Res (Hoboken)
|
2011
|
0.91
|
|
37
|
Relationship between markers of platelet activation and inflammation with disease activity in Wegener's granulomatosis.
|
J Rheumatol
|
2011
|
0.89
|
|
38
|
Novel therapeutic agents for systemic lupus erythematosus.
|
Curr Opin Rheumatol
|
2002
|
0.87
|
|
39
|
Recognition and treatment of juvenile-onset spondyloarthritis.
|
Curr Opin Rheumatol
|
2006
|
0.86
|
|
40
|
Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort.
|
Arthritis Rheum
|
2011
|
0.86
|
|
41
|
Brief report: The value of a patient global assessment of disease activity in granulomatosis with polyangiitis (Wegener's).
|
Arthritis Rheumatol
|
2014
|
0.86
|
|
42
|
MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments.
|
Arthritis Res Ther
|
2011
|
0.85
|
|
43
|
Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial.
|
Arthritis Res Ther
|
2012
|
0.85
|
|
44
|
Regional radiographic damage and functional limitations in patients with ankylosing spondylitis: differences in early and late disease.
|
Arthritis Care Res (Hoboken)
|
2013
|
0.84
|
|
45
|
Ankylosing spondylitis: patterns of radiographic involvement--a re-examination of accepted principles in a cohort of 769 patients.
|
Radiology
|
2010
|
0.81
|
|
46
|
Spinal mobility measures in spondyloarthritis: application of the OMERACT filter.
|
J Rheumatol
|
2007
|
0.79
|
|
47
|
Antiendothelial cell antibodies in patients with Wegener's granulomatosis: prevalence and correlation with disease activity and manifestations.
|
J Rheumatol
|
2007
|
0.79
|
|
48
|
Etanercept in adult patients with early onset ankylosing spondylitis.
|
J Rheumatol
|
2006
|
0.78
|
|
49
|
Evaluation of the patient acceptable symptom state as an outcome measure in patients with ankylosing spondylitis: data from a randomized controlled trial.
|
Arthritis Rheum
|
2008
|
0.78
|
|
50
|
Functional limitations due to axial and peripheral joint impairments in patients with ankylosing spondylitis: are focused measures more informative?
|
Arthritis Care Res (Hoboken)
|
2013
|
0.77
|
|
51
|
Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study).
|
Arthritis Res Ther
|
2014
|
0.77
|
|
52
|
Systemic lupus erythematosus. How to manage, when to refer.
|
Postgrad Med
|
2003
|
0.76
|
|
53
|
Summary of the 2005 annual research and education meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN).
|
J Rheumatol
|
2006
|
0.76
|
|
54
|
Drug insight: anti-tumor-necrosis-factor therapy for ankylosing spondylitis.
|
Nat Clin Pract Rheumatol
|
2006
|
0.76
|
|
55
|
2006 annual research and education meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN).
|
J Rheumatol
|
2007
|
0.76
|
|
56
|
Breaking the ice: Testing tumor necrosis factor alpha blockade in lupus.
|
Arthritis Rheum
|
2004
|
0.75
|
|
57
|
Use of a medication control officer to reduce bias in a clinical trial: lessons learned from the scleroderma lung study.
|
Clin Trials
|
2009
|
0.75
|